ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Sclerosis (MS) in Berlin, BE

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Multiple Sclerosis
Sclerosis
Chronic Progressive Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Autoimmune Diseases
Recurrence
Cognitive Dysfunction

Multiple Sclerosis (MS) trials near Berlin, BE, DEU:

MB-CART2019.1 in Refractory Multiple Sclerosis

assess the feasibility, safety and preliminary efficacy of MB-CART2019.1 in patients with active refractory primary and secondary progressive MS...

Begins enrollment this month
Multiple Sclerosis
CAR T Cell Therapy
Biological: MB-CART2019.1

Phase 1, Phase 2

Miltenyi Biotec
Miltenyi Biotec

Berlin, Berlin, Germany

This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple...

Active, not recruiting
Multiple Sclerosis, Relapsing-Remitting
Drug: Interferon beta type 1a
Drug: BIIB017 (peginterferon beta-1a)

Phase 3

Biogen
Biogen

Berlin, Germany and 65 other locations

as measured by icobrain mr, on the detection of disease activity in multiple sclerosis, including the identification of smouldering...

Invitation-only
Multiple Sclerosis
Radiologically Isolated Syndrome
Device: quantitative brain MRI (icobrain mr)
Other: Standard of Care (SOC)
icometrix

Berlin, State of Berlin, Germany and 5 other locations

This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥1...

Enrolling
Secondary Progressive Multiple Sclerosis
Relapsing Multiple Sclerosis
Drug: Teriflunomide
Drug: Placebo

Phase 3

Sanofi
Sanofi

Berlin, Germany and 352 other locations

) neo-antigen in subjects with relapsing multiple sclerosis (RMS).COVID-19 sub-study:The purpose of this research sub-study is to e...

Active, not recruiting
Relapsing Multiple Sclerosis
Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV)
Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap)

Phase 3

Novartis
Novartis

Potsdam, Germany and 298 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems